Genmab A/S (GMAB:NASDAQ) closed at $43.79 on October 23, 2026, up 9.48% on the day. The stock trades 1.2% below its 52-week high of $44.34 and 85.4% above its 52-week low of $23.62. Over the past year, it gained 46.5%. Genmab A/S is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, GMAB closed higher on 131 days (52%). Its best day was October 5, 2026 (+10.73%) and its worst was March 3, 2026 (-6.71%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 2 times.
Genmab is a cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and its promising first-in-class multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
Find more stocks like GMAB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.